Ocular carteolol: A review of its use in the management of glaucoma and ocular hypertension

Drugs and Aging

Volumn 24, Issue 6, 2007, Pages 509-528

  Henness, Sheridan ^a   Harrison, Tracy Swainston ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARTEOLOL; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; NIPRADILOL; PILOCARPINE; TIMOLOL;

AQUEOUS HUMOR; ASTHMA; BLURRED VISION; BRADYCARDIA; BURNING SENSATION; CATARACT; CILIARY BODY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; DATA BASE; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRY EYE; EMBASE; EPIPHORA; EYE PAIN; EYELID ERYTHEMA; GLAUCOMA; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; IRIS; KERATITIS; LACRIMATION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; MONOTHERAPY; NONHUMAN; OCULAR PRURITUS; OPTIC NERVE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RABBIT; RAT STRAIN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYMPTOM; VISUAL FIELD; VITREOUS DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARTEOLOL; CLINICAL TRIALS; GLAUCOMA; HUMANS; INSTILLATION, DRUG; MIDDLE AGED; OCULAR HYPERTENSION; TREATMENT OUTCOME;

EID: 34250869551     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724060-00007     Document Type: Review

References (82)

1. Alward WLM. Medical management of glaucoma. N Engl J Med 1998 Oct 29; 339 (18): 1298-307
2. American Academy of Ophthalmology. Primary open-angle glaucoma [online]. Available from URL: http://www.aao.org/ [Accessed 2007 Jan 22]
3. The Royal College of Ophthalmologists. Guidelines for the management of open-angle glaucoma and ocular hypertension 2004 [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2007 Jan 22]
4. American Optometric Association. Care of the patient with open angle glaucoma [online]. Available from URL: http://ww-w.aoa.org/ [Accessed 2007 Jan 22]
5. Kroese M, Burton H. Primary open angle glaucoma: the need for a consensus case definition. J Epidemiol Community Health 2003 Sep; 57 (9): 752-4
6. Lee P. Use of guidelines in the management of patients with glaucoma. Dis Manage Health Outcomes 1999 Apr; 5 (4): 187-95
7. Kitazawa Y. Open-angle glaucoma in Japan. J Glaucoma 2001 Oct; 10 (5 Suppl. 1): S5-6
8. Cockburn DM. Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists. Clin Exp Optom 2000 May/Jun; 83 (3): 119-27
9. Goldberg LD. Clinical guidelines for the treatment of glaucoma [online]. Available from URL: http://www. managedcaremag.com/supplements/ 0211_ptd_glaucoma/ptd_glaucoma.pdf [Accessed 2007 Jan 22]
10. Hoyng PFJ, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000 Mar; 59 (3): 411-34
11. Data on file. Otsuka Pharmaceuticals Co., Ltd., 2007
12. Otsuka Pharmaceutical Co., Ltd. Mikelan® ophthalmic solution 1%, Mikelan® ophthalmic solution 2%: prescribing information [online]. Available from URL: http://www.e-search.ne.jp [Accessed 2005 Dec 5]
13. Chrisp P, Sorkin EM. Ocular carteolol: a review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging 1992; 2 (1): 58-77
14. Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers. Ann Pharmacother 1996 Jan; 30: 43-54
15. Apotex Corp. Carteolol HCl ophthalmic solution USP: prescribing information [online]. Available from URL: http://www.apotexcorp.com [Accessed 2005 Dec 20]
16. Araie M, Takase M. Effects of pilocarpine and carteolol, a new beta-adrenergic blocking agent on human aqueous humor dynamics [in Japanese]. Nippon Ganka Gakkai Zasshi 1980 Dec 10; 84 (12): 2085-91
17. Matsuo T, Araie M, Takase M, et al. Effects of carteolol hydrochloride on aqueous humour dynamics in human eyes with glaucoma and ocular hypertension [in Japanese]. Ganka Rinsho Iho 1983; 77 (10): 1654-7
18. Floreani M, Froldi G, Cavalli M, et al. Characterization of intrinsic sympathomimetic activity of carteolol in rat cardiovascular preparations. J Pharmacol Sci 2004 May; 95 (1): 115-23
19. 1-adrenoceptors: a comparison with xamoterol. J Pharmacol Exp Ther 2005 Dec; 315 (3): 1386-95
20. 2- adrenoceptor mediated. Br J Clin Pharmacol 1999 Dec; 48: 875P-6P
21. Jasper JR, Michel MC, Insel PA. The β-adrenoceptor antagonist carteolol and its metabolite 8-hydroxycarteolol have different intrinsic sympathomimetic activities. Br J Clin Pharmacol 1990; 30 Suppl. 1: 109S-11S
22. Pillunat L, Stodtmeister R. Effect of different antiglaucomatous drugs on ocular perfusion pressures. J Ocul Pharmacol 1988 Fall; 4 (3): 231-42
23. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. Br J Ophthalmol 1988 Feb; 72 (2): 101-3
24. Tamaki Y, Araie M, Tomita K, et al. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head. Curr Eye Res 1997 Nov; 16 (11): 1102-10
25. Mizuki K, Yamazaki Y. Effect of carteolol hydrochloride on ocular blood flow dynamics in normal human eyes [in Japanese]. Nippon Ganka Gakkai Zasshi 2000 Apr; 104 (4): 226-31
26. Tamaki Y, Araie M, Tomita K, et al. Effects of topical adrenergic agents on tissue circulation in rabbit and human optic nerve head evaluated with laser speckle tissue circulation analyzer. Surv Ophthalmol 1997 Nov; 42 Suppl. 1: S52-63
27. Mihara M, Matsuo N, Koyama T, et al. Human retinal circulation with carteolol instillation demonstrated by fluorescein video-angiography and image analysis [in Japanese]. Ther Res 1989; 10 (10): 161-7
28. Grunwald JE, Delehanty J. Effect of topical carteolol on the normal human retinal circulation. Invest Ophthalmol Vis Sci 1992 May; 33 (6): 1853-6
29. Coulangeon LM, Sole M, Menerath JM. Aqueous humor flow measured by fluorophotometry: comparative study of the effect of different beta-blocker eye drops in patients with ocular hypertension [in French]. Ophtalmologie 1990; 4 (2): 156-61
30. Höh H, Nastainczyk W. β-blocker und hornhautsensibilität. Fortschr Ophthalmol 1991; 88: 515-21
31. Stewart WC, Shields MB, Allen RC, et al. A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 1991; 229: 258-61
32. Kitazawa Y. Multicenter double-blind comparison of carteolol and timolol in primary open-angle glaucoma and ocular hypertension. Adv Ther 1993 May-Jun; 10 (3): 95-131
33. Famà F, Santamaria S. Comparison of the ocular effects of three beta-blockers: timolol, carteolol, and betaxolol. Ann Ophthalmol Glaucoma 1996 Sep-Oct; 28 (5): 317-20
34. Scoville B, Mueller B, White BG, et al. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988 Feb; 105: 150-4
35. Harris A. Evidence that studying vascular considerations can benefit patients with glaucoma [online]. Available from URL: http://www.wills-glaucoma. org/2003symp/harris.htm [Accessed 2006 Jan 18]
36. Frishman WH, Kowalski M, Nagnur S, et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on β-adrenergic blockade. Heart Dis 2001; 3 (6): 386-97
37. Montanari P, Marangoni P, Oldani A, et al. Color Doppler imaging study in patients with primary open-angle glaucoma treated with timolol 0.5% and carteolol 2%. Eur J Ophthalmol 2001; 11 (3): 240-4
38. Sugiyama, Kojima, Ishida, et al. Changes in optic nerve-head circulation produced by combined therapy with latanoprost and beta-blockers [abstract no. P2-69; in Japanese]. 60th Congress of Clinical Opthalmology of Japan; 2006 October 5-8; Kyoto
39. Altan-Yaycioglu R, Türker G, Akdöl S, et al. The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study. Eur J Ophthalmol 2001; 11 (1): 37-46
40. Chen M-J, Chou JC-K, Chiou H-J, et al. Color Doppler imaging of retrobulbar hemodynamics after topical carteolol in normal tension glaucoma. Chin Med J (Taipei) 2001 Oct; 64: 575-80
41. Stodtmeister R, Pillunat L, Wilmanns I, et al. Effect of topically applied carteolol and timolol on the pressure tolerance of the optic nerve head [in German]. Ophthalmologica 1989; 198 (2): 64-77
42. Pillunat LE, Stodtmeister R, Wilmanns I, et al. Effect of beta receptor blockers on pressure compliance of the optic nerve head [in German]. Fortschr Ophthalmol 1988; 85 (3): 231-4
43. Kuwahara K, Oizumi N, Fujisawa S, et al. Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea 2005 Mar; 24 (2): 213-20
44. Kawai K, Kuwahara K, Oizumi N, et al. Effects of carteolol hydrochloride on the in vitro production of LPS-induced proinflammatory cytokines by murine macrophage. J Ocul Pharmacol Ther 2004 Jun; 20 (3): 237-45
45. Zoia MC, Cerveri I, Bruschi C, et al. Comparison of the effects of timolol and carteolol eye drops on bronchial reactivity in a group of young normal subjects. Ital J Ophthalmol 1992; 6 (1): 15-8
46. Diggory P, Cassels-Brown A, Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Ageing 1996 Nov; 25: 424-8
47. Hugues FC, Le Jeunne C, Munera Y, et al. Comparison of ventilatory and cardiovascular effects of carteolol and metipranolol in asthmatic patients [in French]. J Fr Ophtalmol 1987; 10 (8-9): 485-90
48. Le Jeunne CL, Hugues FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol 1989 Feb; 29 (2): 97-101
49. Le Jeunne C, Bringer L, Mondjee-Tahura Z, et al. Cardiovascular effects of β blockers eye drops (timolol, carteolol, metipranolol, betaxolol) in old patients [in French]. Therapie 1988; 43 (2): 89-92
50. Berlin I, Marcel P, Uzzan B, et al. A single dose of three different ophthalmic beta-blockers antagonizes the chrono-tropic effect of isoproterenol in healthy volunteers. Clin Pharmacol Ther 1987 Jun; 41 (6): 622-6
51. Yamamoto T, Kitazawa Y, Noma A, et al. The effects of the β-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients. J Glaucoma 1996 Aug; 5: 252-7
52. Bartlett JD, Olivier M, Richardson T, et al. Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. J Glaucoma 1999 Dec; 8 (6): 388-95
53. Stewart WC, Dubiner HB, Mundorf TK, et al. Effects of carte-olol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol 1999 Feb; 127: 142-7
54. Tsuboi K, Adachi M, Tanabe M, et al. Effect of topical instillation of 2% carteolol on the serum lipid levels in glaucoma patients [in Japanese]. Rinsho Ganka 1999; 53 (5): 885-8
55. Ishii Y, Nakamura K, Matsuki S, et al. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity. J Clin Pharmacol 2002 Sep; 42 (9): 1020-6
56. Renard P, Kovalski JL, Cochereau I, et al. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2005 Dec; 243 (12): 1221-7
57. Aoyama Y, Fujio N, Hashimoto M, et al. Whole autoradiographic assessment of 14C-carteolol pharmacokinetics [in Japanese]. Atarashii Ganka 1999; 16 (12): 1715-8
58. Fujio N, Kusumoto N, Odomi M. Ocular distribution of carteolol after single and repeated ocular instillation in pigmented rabbits. Acta Ophthalmol (Copenh) 1994 Dec; 72 (6): 688-93
59. 14C-carteolol hydrochloride (β-blocker) in the albino rabbits [in Japanese]. Nippon Ganka Gakkai Zasshi 1984 Feb; 88 (2): 236-41
60. Séchoy O, Tissié G, Sébastian C, et al. A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm 2000 Oct 10; 207 (1-2): 109-16
61. Tissié G, Sébastian C, Elena PP, et al. Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit. J Ocul Pharmacol Ther 2002 Feb; 18 (1): 65-73
62. Kudo S, Uchida M, Odomi M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 1997 Aug; 52: 479-85
63. Hirota A, Mishima H, Kiuchi Y, et al. Effect of topical 8-hydroxy carteolol on intraocular pressure and melanin gran-ules [in Japanese]. Nippon Ganka Gakkai Zasshi 1991 Aug; 95 (8): 752-7
64. Novartis Pharmaceuticals UK Ltd. Teoptic 1% eye drops, Teoptic 2% eye drops: prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Dec 5]
65. Behrens-Baumann W, Kimmich F, Walt JG, et al. A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. Ophthalmologica 1994; 208 (1): 32-6
66. Stewart WC, Cohen JS, Netland PA and the Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol 1997 Oct; 124 (4): 498-505
67. Flammer J, Kitazawa Y, Bonomi L, et al. Influence of carteolol and timolol on IOP and visual fields in glaucoma: a multi-center, double-masked, prospective study. Eur J Ophthalmol 1992 Oct-Dec; 2 (4): 169-74
68. Tsuchisaka H, Kin K, Matsumoto S, et al. Multi-institutional comparative test of timolol and carteolol for glaucomas [in Japanese]. Ganka Rinsho Iho 1991; 85: 1136-40
69. Mirza GE, Karaküçük S, Temel E. Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. J Glaucoma 2000 Feb; 9 (1): 45-50
70. Watson PG, Barnett MF, Parker V, et al. A 7 year prospective comparative study of three topical β blockers in the management of primary open angle glaucoma. Br J Ophthalmol 2001 Aug; 85 (8): 962-8
71. Demailly P, Allaire C, Trinquand C, for the Once-daily Carteolol Study Group. Ocular hypotensive efficacy and safety of once daily carteolol alginate [published erratum appears in Br J Ophthalmol 2001 Dec; 85: 1498]. Br J Ophthalmol 2001 Aug; 85 (8): 921-4
72. Trinquand C, Romanet J-P, Nordmann J-P, et al. Efficacy and safety of long-acting carteolol 1% once daily: a double-masked, randomized study [in French]. J Fr Ophtalmol 2003 Feb; 26 (2): 131-6
73. Yamamoto T, and the Carteolol Long-acting Formulation Study Group. Ocular hypotensive effect of 1% carteolol long-acting eye drops: a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs current product [in Japanese]. Nippon Ganka Gakkai Zasshi 2007 Jun; 111 (6): 463-72
74. Keates EU, Friedland BR, Stewart RH, et al. Carteolol hydrochloride: controlled evaluations of its ocular hypotensive efficacy relative to its vehicle, and, in combination with pilocarpine, relative to timolol. J Glaucoma 1994; 3 (4): 315-22
75. Haneda M, Shirato S, Maruyama K, et al. Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma. Jpn J Ophthalmol 2006; 50 (1): 33-7
76. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma 2006 Aug; 15 (4): 341-5
77. Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol 1997 Apr; 123: 465-77
78. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004 Nov; 82 (11): 844-51
79. Camras CB, Toris CB, Tamesis RR. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging 1999 Nov; 15 (5): 377-88
80. Chauvin Pharmaceuticals Ltd. Minims metipranolol 0.1% w/v: prescribing information [online]. Available from URL: http:// emc.medicines.org [Accessed 2007 Mar 28]
81. Allergan Ltd. Betagan (levobunolol): prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Mar 28]
82. Merck Sharp & Dohme Limited. Timoptol ophthalmic solution 0.25 and 0.5% (timolol): prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Mar 28]